Articles From: Neuberger Berman Real Estate Securities Income Fund Announces Monthly Distribution to Neurocrine Biosciences Announces Conference Call And Webcast To Present Third Quarter 2013 Financial Results


2014/3/31
NEW YORK , March 31, 2014 /PRNewswire/ -- Neuberger Berman Real Estate Securities Income Fund Inc. (NYSE MKT: NRO) has announced a distribution declaration of $0.02 per share of common stock.
Sign-up for Neuberger Berman Real Estate Securities Income Fund Announces Monthly Distribution investment picks
http://media.marketwire.com/attachments/201009/643413_newlogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1041432&ProfileId=051205&sourceType=1 PLAINVIEW, NY --
Sign-up for NeuLion Powers Rogers Cup Live Streaming on Rogers Anyplace TV investment picks
2013/8/9
http://media.marketwire.com/attachments/201009/643413_newlogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1041448&ProfileId=051205&sourceType=1 PLAINVIEW, NY --
Sign-up for NeuLion Reports 26% Increase in Revenue and Third Consecutive Positive Quarter investment picks
http://media.marketwire.com/attachments/201009/643413_newlogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1066474&ProfileId=051205&sourceType=1 PLAINVIEW, NY --
Sign-up for NeuLion Reports Increased Revenue and Fourth Consecutive Positive Quarter investment picks
2014/3/13
http://media.marketwire.com/attachments/201009/643413_newlogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1097660&ProfileId=051205&sourceType=1 PLAINVIEW, NY --
Sign-up for NeuLion Reports Record Fourth Quarter and Year-End Financial Results investment picks
http://media.marketwire.com/attachments/201009/643413_newlogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1048595&ProfileId=051205&sourceType=1 PLAINVIEW, NY --
Sign-up for NeuLion to Present at the 2013 Gateway Conference on September 10 investment picks
2014/1/21
http://media.marketwire.com/attachments/201009/643413_newlogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1083450&ProfileId=051205&sourceType=1 PLAINVIEW, NY --
Sign-up for NeuLion's Hit Web Broadcast 'Digital Dudes' Brings Audiences Exclusive Insights Into Digital Success Stories investment picks
2014/1/8
NeuMovie, a digital platform that allows consumers to watch, rent, and purchase movies, today announced that it has selected CSG Content Direct , the leading end-to-end content monetization and management platform in the world, as the exclusive NeuMovie go-to-market solution for all UltraViolet-based solutions.
Sign-up for NeuMovie™ Selects CSG Content Direct® to Grow Its UltraViolet™ Offerings investment picks
2014/3/10
ROCKVILLE, Md.
Sign-up for Neuralstem Announces 2013 Financial Results investment picks
ROCKVILLE, Md.
Sign-up for Neuralstem Appoints Catherine Angell Sohn To Board Of Directors investment picks
2013/9/26
Ted Harada, ALS Stem Cell Trial Patient, To Talk ROCKVILLE, Md.
Sign-up for Neuralstem CEO To Present At Stem Cells & Regenerative Medicine Congress investment picks
ROCKVILLE, Md.
Sign-up for Neuralstem Closes $20 Million Registered Direct Offering investment picks
Updates on NSI-566 ALS Phase II - cSCI Phase I - Stroke Phase I/II, and NSI-189/MDD Live Audio Webcast to Air on Tuesday, January 14, at 3:30 p.m. PT ROCKVILLE, Md.
Sign-up for Neuralstem President And CEO To Present 2014 Trials Overview At 2014 Biotech Showcase investment picks
Live Webcast on Tuesday, September 10, at 11:40 a.m. EST ROCKVILLE, Md.
Sign-up for Neuralstem President And CEO To Present At The 2013 Rodman & Renshaw Annual Healthcare Conference investment picks
2014/2/6
Live Webcast to Air on Tuesday, February 11, at 3:00 p.m. EST ROCKVILLE, Md.
Sign-up for Neuralstem President and CEO to Present NSI-566 Clinical Trials Program Update at BIO CEO & Investor Conference 2014 investment picks
2014/4/7
Will Also Present Update on Ongoing Phase II Trial ROCKVILLE, Md.
Sign-up for Neuralstem Principal Investigator, Dr. Eva Feldman, To Present Published ALS Trial Phase I Data At Medical Conference investment picks
2013/8/9
ROCKVILLE, Md.
Sign-up for Neuralstem Reports Second Quarter Financial Results And Provides Business And Clinical Update investment picks
ROCKVILLE, Md.
Sign-up for Neuralstem To Raise $19.65 Million In Registered Direct Offering investment picks
ROCKVILLE, Md.
Sign-up for Neuralstem To Raise $4 Million In Registered Direct Offering investment picks
2014/2/10
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1088341&ProfileId=051205&sourceType=1 PODGORICA, MONTENEGRO --
Sign-up for Neuro-Biotech Corp. (MRES.PK) Performs Reverse Merger With the Institute of Biomedical Research investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1074187&ProfileId=051205&sourceType=1 BROOKSVILLE, FL --
Sign-up for Neuro-Hitech, Inc. Announces Corporate Update investment picks
2014/1/3
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1079222&ProfileId=051205&sourceType=1 FORT WORTH, TX --
Sign-up for Neuro-Hitech, Inc. Board Approves Name Change investment picks
2014/3/18
LAVAL, Quebec, March 18, 2014 (GLOBE NEWSWIRE) -- NeuroBioPharm Inc. ("NeuroBio" or the "Corporation"), a Neptune Technologies & Bioressources Inc. subsidiary ("Neptune") (Nasdaq:NEPT) (TSX:NTB), announces that it has extended the life of its Series 2011-1 common share purchase warrants, initiated a royalty prepayment process with Neptune and appointed a new CFO.
Sign-up for NeuroBioPharm Extends Life of Warrants and Provides Other Corporate Updates investment picks
OPEN-LABEL EXTENSION SHOWS A FAVORABLE SAFETY PROFILE AND DYSKINESIA REDUCTION THROUGH 12 WEEKS OF DOSING SAN DIEGO , Jan.
Sign-up for Neurocrine Announces 12-Week Safety Results From Initial Phase IIB Study Of VMAT2 Inhibitor NBI-98854 investment picks
2013/9/9
Company To Host Conference Call And Webcast Monday, September 9th At 5:00PM ET / 2:00PM PT SAN DIEGO , Sept.
Sign-up for Neurocrine Announces Phase IIb Results Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia investment picks
Plans to submit end of phase II meeting request to FDA Company to host conference call and webcast Monday, January 6th at 5:00pm ET / 2:00pm PT SAN DIEGO , Jan.
Sign-up for Neurocrine Announces Positive Results of VMAT2 Inhibitor NBI-98854 in Kinect 2 Study investment picks
2013/10/22
Conference Call and Webcast Scheduled For Tuesday, October 29, 2013 SAN DIEGO , Oct.
Sign-up for Neurocrine Biosciences Announces Conference Call And Webcast To Present Third Quarter 2013 Financial Results investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Neuberger Berman Real Estate Securities Income Fund Announces Monthly Distribution to Neurocrine Biosciences Announces Conference Call And Webcast To Present Third Quarter 2013 Financial Results
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity